{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:56:37Z","timestamp":1773939397316,"version":"3.50.1"},"reference-count":26,"publisher":"e-Century Publishing Corporation","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/yihu2909","type":"journal-article","created":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T06:05:06Z","timestamp":1759039506000},"page":"6795-6810","source":"Crossref","is-referenced-by-count":1,"title":["Network pharmacology-guided investigation of Fuzheng Yanggan Huaxian decoction in a CCL4-induced hepatic fibrosis mouse model: involvement of the TLR4-MAPK\/NF-κB signaling axis and intestinal barrier"],"prefix":"10.62347","volume":"17","author":[{"given":"Jianguo","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","unstructured":"Hammerich L and Tacke F. Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol 2023; 20: 633-646.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","unstructured":"Kisseleva T and Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 2021; 18: 151-166.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","unstructured":"Albillos A, de Gottardi A and Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol 2020; 72: 558-577.","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1111\/jgh.15512","article-title":"Gut-liver-axis: barrier function of liver sinusoidal endothelial cell","volume":"36","author":"Wang","year":"2021","unstructured":"Wang Y and Liu Y. Gut-liver-axis: barrier function of liver sinusoidal endothelial cell. J Gastroenterol Hepatol 2021; 36: 2706-2714.","journal-title":"J Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"176166","DOI":"10.1016\/j.ejphar.2023.176166","article-title":"Canagliflozin ameliorates ulcerative colitis via regulation of TLR4\/MAPK\/NF-κB and Nrf2\/PPAR-γ\/SIRT1 signaling pathways","volume":"960","author":"Althagafy","year":"2023","unstructured":"Althagafy HS, Ali FEM, Hassanein EHM, Mohammedsaleh ZM, Kotb El-Sayed MI, Atwa AM, Sayed AM and Soubh AA. Canagliflozin ameliorates ulcerative colitis via regulation of TLR4\/MAPK\/NF-κB and Nrf2\/PPAR-γ\/SIRT1 signaling pathways. Eur J Pharmacol 2023; 960: 176166.","journal-title":"Eur J Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw S","year":"2008","unstructured":"Reagan-Shaw S, Nihal M and Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661.","journal-title":"FASEB J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"752148","DOI":"10.3389\/fphar.2021.752148","article-title":"Alcohol abstinence rescues hepatic steatosis and liver injury via improving metabolic reprogramming in chronic alcohol-fed mice","volume":"12","author":"Pi","year":"2021","unstructured":"Pi A, Jiang K, Ding Q, Lai S, Yang W, Zhu J, Guo R, Fan Y, Chi L and Li S. Alcohol abstinence rescues hepatic steatosis and liver injury via improving metabolic reprogramming in chronic alcohol-fed mice. Front Pharmacol 2021; 12: 752148.","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/liv.12760","article-title":"8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity","volume":"35","author":"KJ","year":"2015","unstructured":"Fagan KJ, Pretorius CJ, Horsfall LU, Irvine KM, Wilgen U, Choi K, Fletcher LM, Tate J, Melino M, Nusrat S, Miller GC, Clouston AD, Ballard E, O’Rourke P, Lampe G, Ungerer JPJ and Powell EE. ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity. Liver Int 2015; 35: 1673-1681.","journal-title":"Liver Int"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10620-015-3935-y","article-title":"Assessment of the intestinal barrier with five different permeability tests in healthy C57BL\/6J and BALB\/cJ mice","volume":"61","author":"Volynets","year":"2016","unstructured":"Volynets V, Reichold A, Bárdos G, Rings A, Bleich A and Bischoff SC. Assessment of the intestinal barrier with five different permeability tests in healthy C57BL\/6J and BALB\/cJ mice. Dig Dis Sci 2016; 61: 737-746.","journal-title":"Dig Dis Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nrgastro.2016.86","article-title":"Critical comparison of elastography methods to assess chronic liver disease","volume":"13","author":"Friedrich-Rust M","year":"2016","unstructured":"Friedrich-Rust M, Poynard T and Castera L. Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol 2016; 13: 402-411.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/hep.29179","article-title":"Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis","volume":"67","author":"Herrmann","year":"2018","unstructured":"Herrmann E, de Lédinghen V, Cassinotto C, Chu WC, Leung VY, Ferraioli G, Filice C, Castera L, Vilgrain V, Ronot M, Dumortier J, Guibal A, Pol S, Trebicka J, Jansen C, Strassburg C, Zheng R, Zheng J, Francque S, Vanwolleghem T, Vonghia L, Manesis EK, Zoumpoulis P, Sporea I, Thiele M, Krag A, Cohen-Bacrie C, Criton A, Gay J, Deffieux T and Friedrich-Rust M. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis. Hepatology 2018; 67: 260-272.","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"13051","DOI":"10.1073\/pnas.0804280105","article-title":"Short telomeres are a risk factor for idiopathic pulmonary fibrosis","volume":"105","author":"Alder","year":"2008","unstructured":"Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, Vulto I, Xie M, Qi X, Tuder RM, Phillips JA 3rd, Lansdorp PM, Loyd JE and Armanios MY. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 2008; 105: 13051-13056.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41401-024-01454-x","article-title":"Peptidoglycan isolated from the fruit of Lycium barbarum alleviates liver fibrosis in mice by regulating the TGF-β\/Smad7 signaling and gut microbiota","volume":"46","author":"Nie","year":"2025","unstructured":"Nie YM, Zhou WQ, Niu T, Mao MF, Zhan YX, Li Y, Wang KP, Li MX and Ding K. Peptidoglycan isolated from the fruit of Lycium barbarum alleviates liver fibrosis in mice by regulating the TGF-β\/Smad7 signaling and gut microbiota. Acta Pharmacol Sin 2025; 46: 1329-1344.","journal-title":"Acta Pharmacol Sin"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1053\/j.gastro.2014.01.020","article-title":"Interactions between the intestinal microbiome and liver diseases","volume":"146","author":"Schnabl","year":"2014","unstructured":"Schnabl B and Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146: 1513-1524.","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00018-012-1070-x","article-title":"Regulation of intestinal epithelial permeability by tight junctions","volume":"70","author":"Suzuki","year":"2013","unstructured":"Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci 2013; 70: 631-659.","journal-title":"Cell Mol Life Sci"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Odenwald MA and Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol 2017; 14: 9-21.","DOI":"10.1038\/nrgastro.2016.169"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jhep.2012.01.019","article-title":"Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease","volume":"56","author":"Fouts","year":"2012","unstructured":"Fouts DE, Torralba M, Nelson KE, Brenner DA and Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol 2012; 56: 1283-1292.","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/hep.26695","article-title":"Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice","volume":"59","author":"De Minicis","year":"2014","unstructured":"De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, Mingarelli E, Facinelli B, Magi G, Palmieri C, Marzioni M, Benedetti A and Svegliati-Baroni G. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 2014; 59: 1738-1749.","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.7150\/thno.43894","article-title":"Interleukin-22 drives a metabolic adaptive reprogramming to maintain mitochondrial fitness and treat liver injury","volume":"10","author":"Chen","year":"2020","unstructured":"Chen W, Zai W, Fan J, Zhang X, Zeng X, Luan J, Wang Y, Shen Y, Wang Z, Dai S, Fang S, Zhao Z and Ju D. Interleukin-22 drives a metabolic adaptive reprogramming to maintain mitochondrial fitness and treat liver injury. Theranostics 2020; 10: 5879-5894.","journal-title":"Theranostics"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/JLB.5A1119-279R","article-title":"Combination of sivelestat and N-acetylcysteine alleviates the inflammatory response and exceeds standard treatment for acetaminophen-induced liver injury","volume":"107","author":"Raevens","year":"2020","unstructured":"Raevens S, Van Campenhout S, Debacker PJ, Lefere S, Verhelst X, Geerts A, Van Vlierberghe H, Colle I and Devisscher L. Combination of sivelestat and N-acetylcysteine alleviates the inflammatory response and exceeds standard treatment for acetaminophen-induced liver injury. J Leukoc Biol 2020; 107: 341-355.","journal-title":"J Leukoc Biol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"106292","DOI":"10.1016\/j.intimp.2020.106292","article-title":"The c-Met inhibitor capmatinib alleviates acetaminophen-induced hepatotoxicity","volume":"81","author":"Saad","year":"2020","unstructured":"Saad KM, Shaker ME, Shaaban AA, Abdelrahman RS and Said E. The c-Met inhibitor capmatinib alleviates acetaminophen-induced hepatotoxicity. Int Immunopharmacol 2020; 81: 106292.","journal-title":"Int Immunopharmacol"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Chen W, Shen Y, Fan J, Zeng X, Zhang X, Luan J, Wang Y, Zhang J, Fang S, Mei X, Zhao Z and Ju D. IL-22-mediated renal metabolic reprogramming via PFKFB3 to treat kidney injury. Clin Transl Med 2021; 11: e324.","DOI":"10.1002\/ctm2.324"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1016\/j.foodchem.2013.03.061","article-title":"Hepatoprotective effects of eburicoic acid and dehydroeburicoic acid from Antrodia camphorata in a mouse model of acute hepatic injury","volume":"141","author":"Huang","year":"2013","unstructured":"Huang GJ, Deng JS, Huang SS, Lee CY, Hou WC, Wang SY, Sung PJ and Kuo YH. Hepatoprotective effects of eburicoic acid and dehydroeburicoic acid from Antrodia camphorata in a mouse model of acute hepatic injury. Food Chem 2013; 141: 3020-3027.","journal-title":"Food Chem"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/antiox8090395","article-title":"Maltol improves APAP-induced hepatotoxicity by inhibiting oxidative stress and inflammation response via NF-κB and PI3K\/Akt signal pathways","volume":"8","author":"Wang","year":"2019","unstructured":"Wang Z, Hao W, Hu J, Mi X, Han Y, Ren S, Jiang S, Wang Y, Li X and Li W. Maltol improves APAP-induced hepatotoxicity by inhibiting oxidative stress and inflammation response via NF-κB and PI3K\/Akt signal pathways. Antioxidants (Basel) 2019; 8: 395.","journal-title":"Antioxidants (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009; 1: a001651.","DOI":"10.1101\/cshperspect.a001651"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"115817","DOI":"10.1016\/j.taap.2021.115817","article-title":"Pirfenidone attenuates acetaminophen-induced liver injury by suppressing c-Jun N-terminal kinase phosphorylation","volume":"434","author":"Tashiro","year":"2022","unstructured":"Tashiro S, Tanaka M, Goya T, Aoyagi T, Kurokawa M, Imoto K, Kuwano A, Takahashi M, Suzuki H, Kohjima M, Kato M and Ogawa Y. Pirfenidone attenuates acetaminophen-induced liver injury by suppressing c-Jun N-terminal kinase phosphorylation. Toxicol Appl Pharmacol 2022; 434: 115817.","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/9\/ajtr0166112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T09:19:52Z","timestamp":1768987192000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/9\/ajtr0166112.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/yihu2909","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}